Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose

Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):288-9. doi: 10.4103/0378-6323.16628.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Severity of Illness Index
  • Stevens-Johnson Syndrome / chemically induced*
  • Stevens-Johnson Syndrome / physiopathology

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate